Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that poses a growing public health threat. National surveillance data from China (2010-2023) report an overall case fatality rate of approximately 4.8%. However, hospital-based cohorts of severe or critically ill patients report substantially higher rates, ranging from 12% to 30%. Despite its designation as a WHO priority pathogen in 2017, no vaccine has been approved, although a first-in-human Phase I/II trial of an mRNA vaccine candidate was initiated in 2025, and favipiravir, the only authorized antiviral (Japan, 2024), remains of debated clinical benefit, leaving a widening gap between mechanistic understanding and clinical translation. This gap is rooted in the virus’s ability to dismantle the very immune pathways on which vaccines and antivirals depend. The non-structural protein NSs sequesters TBK1, IRF3, and STAT1/STAT2 into viroplasm-like structures, while the nucleoprotein NP induces autophagy-mediated degradation of cGAS and MAVS, collectively diminishing type I interferon responses, impairing B-cell and T-cell immunity, and permitting the dysregulated cytokine storm that is associated with multi-organ failure. These same mechanisms explain why vaccine candidates that perform well in immunocompromised (IFNAR⁻/⁻ or STAT2⁻/⁻) mouse models have not translated to immunocompetent or aged populations, and why antiviral efficacy collapses at high viral loads or late treatment initiation. Unlike prior reviews that treat pathogenesis, antivirals, and vaccines as separate topics, this review integrates them into a single framework linking viral immune evasion to the failure modes of current countermeasures, and identifies the specific obstacles that must be overcome before clinical translation: missing correlates of protection, immunocompromised animal models, and reassortment-driven antigenic diversity. We conclude by outlining priority directions, including AI-assisted antigen design, host-directed and combination therapies, standardized animal models, and integrated One Health surveillance.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular and Infection Microbiology
Published
2026-11-18
DOI
https://doi.org/10.3389/fcimb.2026.2002250
Primary Topic
Viral Infections and Vectors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects

Jian Shang, Amin Ullah, Mei Yang, Lili Li
1 links
Frontiers in Cellular and Infection Microbiology
Viral Infections and Vectors
article

Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects

Jian Shang, Amin Ullah, Mei Yang, Lili Li
article en

Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that poses a growing public health threat. National surveillance data from China (2010-2023) report an overall case fatality rate of approximately 4.8%. However, hospital-based cohorts of severe or critically ill patients report substantially higher rates, ranging from 12% to 30%. Despite its designation as a WHO priority pathogen in 2017, no vaccine has been approved, although a first-in-human Phase I/II trial of an mRNA vaccine candidate was initiated in 2025, and favipiravir, the only authorized antiviral (Japan, 2024), remains of debated clinical benefit, leaving a widening gap between mechanistic understanding and clinical translation. This gap is rooted in the virus’s ability to dismantle the very immune pathways on which vaccines and antivirals depend. The non-structural protein NSs sequesters TBK1, IRF3, and STAT1/STAT2 into viroplasm-like structures, while the nucleoprotein NP induces autophagy-mediated degradation of cGAS and MAVS, collectively diminishing type I interferon responses, impairing B-cell and T-cell immunity, and permitting the dysregulated cytokine storm that is associated with multi-organ failure. These same mechanisms explain why vaccine candidates that perform well in immunocompromised (IFNAR⁻/⁻ or STAT2⁻/⁻) mouse models have not translated to immunocompetent or aged populations, and why antiviral efficacy collapses at high viral loads or late treatment initiation. Unlike prior reviews that treat pathogenesis, antivirals, and vaccines as separate topics, this review integrates them into a single framework linking viral immune evasion to the failure modes of current countermeasures, and identifies the specific obstacles that must be overcome before clinical translation: missing correlates of protection, immunocompromised animal models, and reassortment-driven antigenic diversity. We conclude by outlining priority directions, including AI-assisted antigen design, host-directed and combination therapies, standardized animal models, and integrated One Health surveillance.

Frontiers in Cellular and Infection MicrobiologyVol. 16
Zhengzhou University (CN)
Zhengzhou University
Good health and well-being
Viral Infections and Vectors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon